Clinical Report: Implant May Modify DR Progression
Overview
The investigational drug PER-001, delivered via a dissolvable intravitreal implant, shows promise in modifying the progression of diabetic retinopathy (DR) and improving visual outcomes. Phase 2 trials demonstrated significant gains in visual acuity and retinal structure in patients with DR.
Background
Diabetic retinopathy is a leading cause of vision loss among working-age adults, making effective treatment options critical. Current therapies primarily focus on preventing further deterioration rather than reversing damage. The development of PER-001 represents a potential shift in the treatment paradigm by targeting underlying ischemia in the retina.
Data Highlights
| Trial | Patient Group | Key Findings |
|---|---|---|
| Phase 2a DR Trial | 27 patients | Improvements in contrast sensitivity, visual acuity, and peripheral visual field |
| Phase 2 Glaucoma Trial | 33 patients | 37.5% of high-dose patients had ≥7 dB improvement in visual field |
Key Findings
- PER-001 is an endothelin receptor antagonist delivered via a biannual intravitreal implant.
- In the DR trial, patients showed measurable gains in contrast sensitivity and visual acuity under low luminance.
- Imaging indicated structural improvements consistent with reduced macular ischemia and microaneurysm burden.
- Safety and tolerability were favorable with no significant safety concerns reported over 24 weeks.
- Plans for phase 2b/3 trials are set for later in 2025.
Clinical Implications
The results from the PER-001 trials suggest a potential new treatment avenue for diabetic retinopathy that may alter disease progression. Clinicians should consider the implications of these findings in managing patients with DR, particularly those with limited options for reversing visual impairment.
Conclusion
The promising results from the PER-001 trials could represent a significant advancement in the treatment of diabetic retinopathy, potentially offering a therapy that modifies the disease course rather than merely preventing further deterioration.
References
- Retinal Physician, 2019 -- Steroid Implants in the Diabetic Macular Edema Treatment Paradigm
- Ophthalmology Management, 2022 -- GLAUCOMA MANAGEMENT GETS AN INTRACAMERAL THERAPY
- PubMed, 2026 -- Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026
- ScienceDirect, 2025 -- Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results From the RHONE-X Extension Trial
- Archives of Orthopaedic and Trauma Surgery — Chronic infections of knee megaprostheses: are “Off-Label” DAIR-Plus or partial two-stage exchange viable options?
- Sustained Success of Customized 3D Printed Titanium Implants in Complex Pelvic Reconstruction: Insights from 106 Cases Over a Decade
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 - PubMed
- Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results From the RHONE-X Extension Trial - ScienceDirect
- Retinal Sensitivity and Retinal Perfusion in Diabetic Retinopathy | Diabetic Retinopathy | JAMA Ophthalmology | JAMA Network
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.